RESEARCH

A Scenario-Based Virtual Patient Program to Support Substance Misuse Education

Leon Zlotos, PhD,^a Ailsa Power, PhD,^a Duncan Hill, BS,^b Paul Chapman, PhD^c

^a NHS Education for Scotland, Glasgow, Scotland

^b NHS Lanarkshire, Airbles Road Centre, Motherwell, Scotland

^c Digital Design Studio, Glasgow School of Art, Glasgow, Scotland

Submitted February 17, 2015; accepted May 27, 2015; published April 25, 2016.

Objective. To evaluate virtual patient (VP) programs for injecting equipment provision (IEP) and opiate substitution therapy (OST) services with respect to confidence and knowledge among preregistration pharmacist trainees.

Methods. Preregistration trainee pharmacists pilot-tested the VP programs and were invited to complete pre/post and 6-month assessments of knowledge and perceived confidence.

Results. One hundred six trainees participated and completed the pre/postassessments. Forty-six (43.4%) participants repeated the assessments at six months. Scores in perceived confidence increased in all domains at both time points postprogram. Knowledge scores were greater posteducation than preeducation. Knowledge scores were also greater six months after education than preeducation. Knowledge scores at six months were lower than posteducation for both programs.

Conclusion. Virtual patients programs increased preregistration pharmacists' knowledge and confidence with regard to IEP and OST immediately after use and at six months postprogram. There was a loss of clinical knowledge over time but confidence change was sustained.

Keywords: e-learning; pharmacy education; simulation; virtual patients; web-based learning.

INTRODUCTION

In Scotland, substance (drugs and alcohol) misuse services are delivered in nearly all community pharmacies, with approximately 84% offering IEP or OST.¹ Patients using these services may also attend hospitals for a range of reasons, from presentation at accident and emergency to scheduled procedures, and require support from the pharmacy staff in the hospitals. The vast number of patients means there is no stereotypical substance misuser. The range of substances being misused is wide, from caffeine or tobacco to alcohol, prescribed analgesics and strong opioids (eg, heroin). Prescription analgesics are becoming more commonly misused but variation exists between localities, populations, and cultures.² The drug using population is aging and as a result, there is an increase in the number of age-related conditions also being presented.3

From the turn of the twenty-first century, substance misuse services delivered at Scottish community pharmacies have increased in range and prevalence: not solely

Corresponding Author: Leon Zlotos, NHS Education for Scotland, 2 Central Quay, 89 Hydepark St., Glasgow, G3 8BW, Scotland. Tel: 0141-2231616. Fax: 0141-2231403. E-mail: leon.zlotos@nes.scot.nhs.uk opioid substitution therapy (OST) but injecting equipment provision (IEP), the supervision of disulfiram, and alcohol brief interventions. All are intended to improve the health of the population and not just those at the highest risk.⁴

Given the increased provision of these services, in particular OST and IEP, pharmacist education is essential to deliver safe, effective, and patient-centered care. Many opioid users feel stigmatized⁵ as can others using IEP or other treatment services. Feelings of stigma can be a barrier to treatment progress⁵ and education should be targeted at the nature of addiction and the opportunities to put patients at ease.⁶

Historically, pharmacist education in substance misuse allayed some of the concerns and fears staff had and assisted in reducing prejudices. Staff attitude was correlated with service provision and enhanced service delivery.⁷ However, evaluation of structured educational sessions for pharmacists indentified minimal change in attitude to methadone programs.⁸ Traditionally, education aimed at addressing these issues has been either by didactic lecturing, role play scenarios, or written distance learning materials (eg, NHS Education for Scotland (NES) Substance Misuse Pack).⁹ Specialist Pharmacists in Substance Misuse (SPiSMs) deliver lectures at undergraduate level in Scotland, which are introductory in nature, and also a tutorial during preregistration training as part of the NES Pre-Registration Pharmacist Scheme (PRPS). Some students may obtain further experience from part-time employment in a community pharmacy.

Education is evolving with an increased use of technology. The potential advantages and disadvantages of using technology in health professions education are well documented.¹⁰⁻¹⁴ The benefits of using technology include reduced staff time,¹² remote accessibility, self directed and self paced content,^{8,12} provision of rapid and up-to-date feedback,¹⁰ easily updatable content,¹⁰ and delivering a consistent message.¹⁵ Educators are able to monitor learning activities and assess learning outcomes, while learners experience greater flexibility and interactivity compared to traditional large group education.¹⁴ Reviews attempting to evaluate the effectiveness of technology in education compared to traditional educational methods highlight that technology enhanced methods can be as effective as traditional method.¹⁵⁻¹⁹

In the field of substance misuse, online education for pharmacists has been developed and evaluated in New Zealand.²⁰ The approach replaced a 3-4 hour training session and resulted in improved attitudes of trained community pharmacists toward patients receiving OST, as well as improvements in confidence and skills. Participants stated that the online format was "feasible and highly acceptable." In addition to online modules, online virtual patients are used in educating health professionals,^{21,22} with increased use in pharmacy education over the last decade.²³⁻³¹ Virtual patient programs allow learners to gain experience by making and learning from decisions in a safe environment,²⁵ thus supporting the active experimentation stage of experiential learning theory.³² The inclusion of "scenario-based" virtual patient programs can be effective where strategic, rather than procedural, learning goals are required. They also provide an opportunity to experience problems with no black and white solution,³³ a situation pharmacists report disliking.34

Pharmacists providing substance misuse services are required to make ethical decisions, the consequences of which may be significant. For example, patients who are stabilized on long-term methadone treatment may request a supply of clean injecting equipment from pharmacists providing IEP services. Choosing to supply this equipment could increase the likelihood of overdose from the combination of illicit substances and prescribed methadone. Conversely, refusing to supply the equipment may lead to the transmission of blood borne infections from equipment sharing. Given the potential significance of these consequences, virtual patient technology appears to be well suited for education in this context. However, there are no published reports of their use.

The aim of this study was to develop and pilot-test two scenario-based virtual patient programs to educate preregistration pharmacists on injecting equipment provision (IEP) and opiate substitution therapy (OST) services in the community pharmacy setting. Preregistration training in Scotland is a 12-month experiential program within a patient-facing setting under the supervision of an appropriately trained pharmacist. Trainees have direct contact with patients, including those requiring substance misuse services. This paper describes the implementation and evaluation of these scenarios aimed at improving preregistration pharmacists' knowledge and confidence in the provision of these services during a year of experiential learning.

METHODS

Two virtual patient scenarios relating to IEP and OST were developed using computer graphics technology. This included a motion capture system to acquire realistic human motion including complex human movement such as injecting drugs. Professional voice artists were recorded and dubbed onto the high definition prerendered computer animations before embedding all media into the Adobe Flash, (Adobe Systems Incorporated, San Jose, CA) runtime environment. This resulted in a virtual patient package that could run on a wider variety of computer specifications without the need for the latest graphics card technology (Digital Design Studios, Glasgow, Scotland, UK).

The learning outcomes were developed for NES by the SPiSMs. Content targeting these outcomes was story boarded then incorporated into the technology. The program was then reviewed by SPiSMs and NES. The program included scenarios during which users were presented periodically with 3-4 choices and the outcome of their decision was played out in the program (Figure 1). Users were allowed one attempt but all alternative outcomes were played out following the outcome relating to the user's choice. No data were collected relating to choices made by individual users.

Preregistration trainees were chosen for this pilot program to give them the experience of providing substance misuse services without risk of personal or patient safety. All 106 trainees enrolled in the 2013-2014 NES preregistration training in the west of Scotland were included. All other trainees and staff were excluded. Trainees participated in the pilot as part of



Figure 1. Example Screenshot of Learner Choices in the Virtual Patient Program.

a mandatory educational program. Trainees were allocated to use the program on one of eight sessions, hosted in a class room environment with a capacity of 16 trainees in each session. This setting was selected because there were sufficient computers with adequate hardware and bandwidth specifications, for each trainee to work individually and IT support was also available.

To evaluate participant confidence and knowledge of subject matter, assessments for each scenario were designed by SPiSMs and piloted by six preregistration trainees from the year preceding the study cohort. Only minor typographical changes were made to the assessments, and these trainees were excluded from the study. The confidence domains were the learning outcomes for the program and related to respecting patients, identifying barriers to access of care, identifying drug misuse symptoms, developing empathy, and understanding harm reduction (Table 1). The SPiSMs determined the underpinning knowledge that is necessary for any pharmacists to be able to provide such services competently in practice, and this was used to inform the knowledge-based questions. The finalized assessments were made available before and immediately after each scenario was used in the classroom. Participants from each session took the assessments simultaneously under invigilation.

The same assessments were made available, via an e-mailed web link, at six months after the trainees had participated in the classroom session. Participants could complete the 6-month assessment in their own time. There was no incentive for trainees to complete this assessment. Assessments contained the same questions at each time point but participants were unaware of this, prior to taking them, and participants were not permitted to take notes during the classroom assessments. For each scenario, confidence was measured using a group of four and five questions with a 5-point Likert scale for OST and IEP, respectively. Knowledge was assessed using 20 multiple-choice questions, subdivided in to five categories, for each scenario. All assessments were hosted on Questback (Questback, Olso, Norway).

Assessment data were extracted to Microsoft Excel and pre/post and 6-month data were matched according to individual participants before analysis. Wilcoxon signed rank test was used to investigate the difference in confidence and knowledge reported at each time point. For participants who completed all assessments, a Friedman's pairwise comparison was used to investigate the overall difference in scores at each time point. The Wilcoxon signed rank test (with Bonferroni correction, p=0.0167) was used to determine the difference in score between each assessment. McNemars and Binomial exact tests were used investigate the difference between knowledge scores for individual questions, where appropriate. Formal ethical approval was not required as the NES research governance group considered this piece of work as course evaluation. Guidance from the Chief Scientist Office for NHS Scotland was consulted.

RESULTS

One hundred six preregistration trainees from the west of Scotland region participated in the pilot program and completed the pre/postassessments. Forty-six (43.4%) trainees completed the assessment at six months.

American Journal of Pharmaceutical Education 2016; 80 (3) Article 48.

| | | IEP | | | OST | |
|--|----------------------------------|-----------------------------------|---------------------------------------|----------------------------------|-----------------------------------|---------------------------------------|
| | (n=106) | | (n=46) | (n=106) | | (n=46) |
| Confidence Domain | Pretest Median Score (IQR) | Posttest Median Score (IQR) | 6-Month Test Median Score (IQR) | Pretest Median Score (IQR) | Posttest Median Score (IQR) | 6-Month Test Median Score (IQR) |
| Understanding the need to respect for patients irrespective of their circumstances | 4 (4-4) | 4 (4-5) ^a | 4 (4-5) ^b | 4 (4-5) | 4 (4-5) ^a | 4 (4-5) ^c |
| Describing the barriers of socioeconomic circumstances to accessing care from a patient's perspective | 3 (3-4) | 4 (4-5) ^a | 4 (4-5) ^b | 4 (4-4) | 4 (4-5) ^a | 4 (4-5) ^b |
| Recognising drug misuse symptoms | 3 (2-4) | $4 (4-5)^{a}$ | $4 (4-5)^{b}$ | 4 (4-4) | $4 (4-5)^{a}$ | $4 (4-4)^{c}$ |
| Developing empathy and understanding of the patient's lifestyle | 4 (3-4) | 4 (4-5) ^a | 4 (4-5) ^b | 4 (4-4) | 4 (4-5) ^a | 4 (4-5) ^b |
| Understanding the meaning of "harm reduction" | - | - | - | 4 (3-4) | 4 (4-5) ^a | 4 (4-5) ^c |

Table 1. Self-rated Level of Confidence Preintervention, Immediately Postintervention and at Six Months Postintervention

^aPosttest confidence was significantly greater than pretest confidence (Wilcoxon signed rank test, p < 0.0001)

^b6 months confidence was significantly greater than pretest confidence (Wilcoxon signed rank test, p < 0.01)

^c6 months confidence was significantly greater than pretest confidence (Wilcoxon signed rank test, p < 0.05)

All trainees self rated their perceived levels of confidence in specified domains preexperience, postexperience, and 6 months later. Table 1 shows that confidence increased significantly in all domains after using the program.

All trainees took the knowledge assessment before and after the program, and there was a significant increase in test scores immediately after using the program (Table 2). For the 46 participants who completed the knowledge assessment pre, post and at 6 months, the greatest knowledge scores were observed immediately after completing the program, followed by the scores at six months. Friedman's pairwise comparison indicated a significant difference between the three assessments for both the IEP ($\chi^2=64$, p<0.001) and OST ($\chi^2=77$, p<0.001). A pairwise application of the Wilcoxon signed rank test (with Bonferroni correction, p=0.017) indicated that there was a significant improvement between prescores and postscores for IEP (Z=5.8, p<0.001) and OST (Z=5.9, p<0.001). This was also true for the preprogram and 6-month scores for IEP (Z=2.6, p<0.017) and OST (Z=4.8, p<0.001). However, there was a significant decrease in scores between the posttest and 6-month test scores for both scenarios (IEP, Z=5.50, p<0.001: OST, Z=5.8, p<0.001).

Analysis of responses to individual questions revealed there was a significant improvement for the majority of questions in both scenarios when comparing preassessment to postassessment (McNemar's test, Tables 3 and 4). There were three of 20 (15%) and five of 20 (25%) questions that were answered significantly better at six months than in the preassessment for the IEP and OST scenarios, respectively (Binomial exact test, Tables 3 and 4).

| Table 2. Knowledge Assessment Scores Preintervention, Immediately Postintervention and at Six Months Postinterv |
|---|
|---|

| | Pretest (n=106) median (IQR) | Posttest (n=106) median (IQR) | Wilcoxon Signed rank test pre vs post (n=106) | 6-month (n=46) median (IQR) | Wilcoxon Signed rank test pre vs 6 months (n=46) | Wilcoxon Singed rank test post vs 6 months (n=46) |
|--|---------------------------------------|--|--|--------------------------------------|---|--|
| Injecting Equipment Provision (IEP) | 14 (12-16) | 19 (17-20) | Z=8.6 ^a | 16 (14-17) | Z=2.6 ^b | Z=5.5 ^a |
| Opioid substitution (OST) | 14 (12-15) | 19 (18-20) | Z=8.9 ^a | 16 (14-17) | Z=4.8 ^a | Z=5.8 ^a |

Significant improvement: ${}^{a}(p < 0.001), {}^{b}(p < 0.05)$

Table 3. Injecting equipment provision (IEP) Individual Knowledge Question Scores Preintervention, Immediately Postintervention, and at Six Months Postintervention

| | Pre (n=106) No. correct (%) | Post (n=106) No. correct (%) | 6 Month (n=46) No. correct (%) |
|---|--------------------------------|---------------------------------|-----------------------------------|
| Which of the following are commonly spread through the sharing of injecting equipment? | | | |
| Hepatitis B virus (HBV) (T) | 86 (81.1) | $96(90.6)^{a}$ | 40 (86.9) |
| Hepatitis C virus (HCV) (T) | 91 (85.8) | 97 (91.5) | 39(84.8) |
| Human Immunodeficiency Virus (HIV) (T) | 94 (88.7) | 95 (89.6) | 38 (82.6) |
| HBC, HCV and HIV (T) | 84 (79.2) | $104 (98.1)^{d}$ | 41 (89.1) |
| With respect to blood borne viruses (true/false): | r. | x 7 | x v |
| The majority of those who contract hepatitis C virus experience obvious symptoms within 1-2 years (F) | 64(60.4) | 103 (97.2) ^d | 26 (56.5) |
| There is a vaccine for hepatitis C virus. (F) | 64 (60.4) | 96 (90.6) ^d | $42(91.3)^{a}$ |
| Pain on passing urine is a possible symptom of gonorrhoea and chlamydia. (T) | 99 (93.4) | 102 (96.2) | 46 (100) |
| Flu-like symptoms are a long-term complication of hepatitis C virus (T) | 28 (26.4) | $92(86.8)^{d}$ | 8 (17.4) |
| With respect to heroin use (true/false): | | | |
| Naloxone injection can be supplied to users of heroin if they are trained in its use (T) | 91 (85.8) | $105(99.1)^{c}$ | 45 (97.8) |
| Aggression is a sign of heroin overdose (F) | 78 (73.6) | $95(89.6)^{\circ}$ | 32 (69.6) |
| When smoking heroin the user feels the effect more quickly than when injecting (F) | 87 (82.1) | $103(97.2)^{c}$ | 35 (76.1) |
| Using heroin rectally is the least harmful way to use it (F) | 65 (61.3) | 99 (93.4) ^c | 23 (50) |
| With respect to heroin administration (true/false): | | | |
| The groin is the safest site to inject heroin (F) | 97 (91.5) | $106 (100)^{b}$ | 46 (100) |
| Heroin can be safely dissolved in flat mineral water (T) | 18 (17) | $103(97.2)^{d}$ | 21 (45.6) ^b |
| White vinegar can safely be used to help dissolve heroin for injection (F) | 70 (66) | $103(97.2)^{d}$ | 32 (69.6) |
| Lemon juice should not be used to dissolve heroin as it can contain a fungus which can | 66 (62.3) | $99(93.4)^{d}$ | $42(91.3)^{b}$ |
| damage the eyes and cause blindness (T) | | | |
| Which of the following is the least harmful way to use heroin? | | | |
| Smoking (T) | 83 (78.3) | 82 (77.4) | 33 (71.7) |
| Injecting (F) | 80 (75.5) | 79 (74.5) | 43 (93.5) |
| Snorting (F) | 57 (53.8) | $102(96.2)^{d}$ | 42 (91.3) |
| Rectal use (F) | 52 (49.1) | 80 (75.5) ^d | 31 (67.4) |
| McNemars and Binomial exact tests were used to test for difference between prescores and postscores, and prescores an Significant difference: $(p<0.05)$, ^a $(p<0.01)$, ^b $(p<0.001)$, ^c $(p<0.001)$ ^d | d 6-month scores, res | spectively | |

American Journal of Pharmaceutical Education 2016; 80 (3) Article 48.

| hs | | |
|---------|---------|--|
| Mont | | |
| Six | | |
| and at | | |
| ion, a | | |
| ervent | | |
| stinte | | |
| ely Pc | | |
| ediate | | |
| Imm | | |
| ntion, | | |
| terve | | |
| Prein | | |
| cores | | |
| ion S | | |
| Quest | | |
| edge | | |
| Iwon | | |
| lual K | | |
| hivid | | |
| ST) Ir | | |
| y (05 | | |
| therap | | |
| tion 1 | | |
| ıbstitu | | |
| ate su | tion | |
| I. Opi | erven | |
| able 4 | ostinto | |
| E | Ā | |

| | Pretest (n=106) | Posttest (n=106) | 6 Months (n=46) |
|---|------------------------------|-------------------------|------------------------|
| | No. correct (%) | No. correct (%) | No. correct (%) |
| With respect to heroin (true/false): | | | |
| Stopping heroin abruptly can be fatal (F) | 27 (25.5) | 96 (90.6) ^d | 27 (58.7) ^b |
| Pregnant patients using heroin should be taken off it immediately (F) | 84 (79.2) | $96(90.6)^{a}$ | 36 (78.3) |
| Heroin withdrawal peaks in the first 24 hrs and subsides after 2-3 days (F) | 30 (28.3) | $86(81.1)^{d}$ | 11 (23.9) |
| The highest risk for a patient returning to drug use after detox is overdose (T) | 102 (96.2) | 104(98.1) | 46 (100) |
| The following are symptoms of heroin withdrawal (true/false): | | | |
| Seizures (F) | 21 (19.8) | 71 (67) ^d | $18(39.1)^{a}$ |
| Muscle and bone pain (T) | 84 (79.2) | $102 (96.2)^{c}$ | 42 (91.3) |
| Anxiety (T) | 104(98.1) | 106 (100) | 46 (100) |
| Diarrhoea (T) | 93 (87.7) | $102(96.2)^{a}$ | 43 (93.5) |
| This drug can be used to relieve opiate withdrawal symptoms (true/false): | ~ | | |
| Mebeverine for stomach cramps and diarrhoca (T) | 91 (85.8) | $104 (98.1)^{a}$ | 41 (89.1) |
| Haloperidol for psychotic episodes (F) | 23 (21.7) | $103(97.2)^{d}$ | $20(43.5)^{b}$ |
| Ibuprofen for aches and pains (T) | 92 (86.8) | $106(100)^{\circ}$ | 43 (93.5) |
| Amitriptyline for depression (F) | 25 (23.6) | $96(90.6)^{d}$ | 20(43.5) |
| The following are advantages of methadone over heroin (true/false): | ~ | ~ | ~ |
| The sedative effects of methadone are shorter (F) | 29 (27.4) | $92 (86.8)^{d}$ | 27 (58.7) ^b |
| Being in a treatment programme reduces the potential of committing crime (T) | 98 (92.5) | 104(98.1) | 46 (100) |
| There is less likelihood of contracting and spreading blood-borne viruses (T) | 105 (99.1) | 103 (97.2) | 45 (97.8) |
| Children of drug misusers are better off if parents are in a treatment program (T) | 105(99.1) | 103 (97.2) | 46 (100) |
| With respect to suboxone (true/false): | | | |
| The drug is a mixture of buprenorphine and naloxone in a ratio of 4:1 (T) | 94 (88.7) | $105 (99.1)^{b}$ | 42 (91.3) |
| Initial doses should be supervised by the nurse or doctor (T) | 85 (80.2) | $103 (97.2)^{\circ}$ | 44 (95.7) |
| Only one dose should be given on the first day because of the risk of overdose (F) | 38 (35.8) | $102 (96.2)^{d}$ | $30(65.2)^{a}$ |
| The naloxone in suboxone does not block the effect of buprenorphine when taken | 82 (77.4) | $94 (88.7)^{a}$ | 41 (89.1) |
| sublingually (T) | | | |
| McNemars and Binomial exact tests were used to test for difference between prescores and postsco similarity in the ference of 0.000 and 0.000 between prescores and postsco | res, and prescores and 6-mon | th scores, respectively | |
| Digititically utility $(p \sim 0.00)$, $(p \sim 0.01)$, $(p \sim 0.001)$, $(p \sim 0.0001)$ | | | |

American Journal of Pharmaceutical Education 2016; 80 (3) Article 48.

DISCUSSION

The aim of this study was to evaluate two virtual patient programs for IEP and OST services, with respect to confidence and knowledge, for preregistration pharmacist trainees. There was an increase in knowledge and confidence immediately after use and six months after. The self-reported level of confidence for learners was significantly higher immediately after using the virtual patient program than prior to use. The increased confidence level was maintained six months later. There was a significant increase in knowledge scores immediately after using the program than prior to use.

Almost half the trainees completed a knowledge test at six months after the program and for these participants the highest scores were observed immediately after completing the program, followed by the scores at six months. There was a significant improvement for the majority of questions in both scenarios when comparing pre/postassessments. Generally, at six months the knowledge scores for each question were higher than prior to using the program. Learning during their experience in practice may have contributed to the retention of knowledge.

Before participating in the program, it was expected that trainees had had limited experience of providing substance misuse services. During their 1-year preregistration training, which was work-based in a pharmacy setting, the participants were likely to have immediate increased exposure to this patient group. The program successfully increased the confidence of the trainees when working with and caring for this patient group with their self-reported level of confidence score being significantly higher after using the program in all areas assessed. Trainees need confidence supporting this patient group because it can influence pharmacist involvement in such services.²⁰ In Scotland, there is little opportunity for pharmacists to avoid providing substance misuse services.

Within the virtual patient scenarios, learners were able to watch the consequences of their decisions as pharmacists being played out within the patient's home environment. Participants reported increased confidence in developing empathy with this patient group, which may be because they could appreciate the challenges these patients encounter at home. The experience may also allow future pharmacists to build realistic expectations of pharmaceutical care with this patient group. The program supports previous research where education increased confidence dealing with challenges associated with and improved attitudes toward this patient group.^{7,20} This form of learning also supports the decision-making process when dealing with real-life scenarios.

There was a significant increase in knowledge scores immediately after using the program, with some retention six months later. In the United Kingdom, services are delivered more frequently in community pharmacies than specialist centres or clinics. Trainees predominantly experience this through OST supervised administration and instalment dispensing. Patients visit the pharmacy more frequently when initiating therapy, which is a time of greater risk. National guidelines recommend a minimum of three months of daily supervision as treatment is initiated to increase patient safety.^{35,36} Trainees should be knowledgeable in this subject area because as they are likely to experience a daily consultation with these patients. One strength of the program is that the learners can test their clinical and ethical decision-making skills, dynamically controlling the patient story in a simulated environment.

With IEP, analysis of responses to individual questions revealed there were three questions answered significantly better at six months than in the preassessment. One was concerning the hepatitis C vaccine, which was topical at the time of the study. The other two questions related to heroin administration. This may be a topic that a substance misuse patient would discuss with a pharmacist. For the OST scenario, the questions answered significantly better at six months were again issues that trainees may have experienced in practice (eg, using haloperidol for psychotic episodes).

Although knowledge scores were lower at six months than immediately after using the program, the majority of the knowledge scores at this point were higher than the preassessment scores. Cook et al stated that the majority of published research outcomes with virtual patient technology were largely focused on short-term knowledge.²² Our research demonstrates knowledge gains immediately and at six months.

To our knowledge, there are no published evaluations of virtual patient technology to support substance misuse education, this is the only postgraduate research carried out on students with a master's degree who undertook a year of practical experience afterwards. Jabbur-Lopes et al concluded that more resources should be invested in developing virtual patient technology specifically for teaching at a graduate level.³⁷ Cook et al concluded the role of virtual patients in postgraduate and continuing education requires further study.²²

Much of the literature looks at teaching students clinical skills with chronic disease conditions^{25,38-43} or determines student satisfaction with the learning experience^{44,45} and the perceived value and useability of the virtual patient tools.⁴⁶ Our research looked at not only increasing knowledge but improving confidence with a challenging patient group. Research could be carried out using this teaching method in other similarly challenging groups. In response to the findings of this study, a series of shorter scenarios relating to recovery and the provision of unscheduled care services are in development.

A limitation of this study was that not all the participants completed the 6-month assessment. In addition, the sample size and the fact that all participants were preregistration trainees may limit the generalizability of the findings. Although this study investigated knowledge and confidence, there was no assessment of competence in practice.

The trainees were practicing in a real-life environment, which varied depending on the training site(s) and patient population for each trainee. All trainees in the PRPS should have had real-life experience with OST/IEP service provision as part of their core training. Therefore, the conclusion that knowledge and confidence as a result of the program is maintained at six months is confounded.

Questions were kept consistent at each assessment but participants could have checked reference sources before the 6-month assessment. To minimize this, participants were not made aware that they would be asked the same questions at the 6-month point.

The questions in the assessments were worded in a multiple true/false format, which limited assessment to participants' factual recall of information only. In addition, the four questions in section 5 of the IEP assessment (Table 3) only assessed the participants' knowledge of one fact. Future studies would benefit from using a format that allows for the assessment of higher-order thinking.

Future research could also assess if this type of education improves competence in practice and, although this pilot-test was conducted in a class room setting, the same technology could be used in a large lecture theater, small group tutorial, or individually on a laptop or mobile device.

CONCLUSION

Using a virtual patient program as a means of training postgraduate trainees on how to deliver pharmaceutical care to substance misuse patients was successful at increasing confidence and knowledge immediately after and at six months after the intervention. This study showed a gradual loss of clinical knowledge over time despite students maintaining confidence.

ACKNOWLEDGMENTS

The authors would like to acknowledge the support offered by Stephen Peddie, lead pharmacist for the Pre-Registration Pharmacist Scheme, NES, and NES Pharmacy for funding the initial development of the virtual patient program.

REFERENCES

1. Community Pharmacy Scotland (personal communication April 8, 2015).

2. Commissioning Treatment for Dependence on Prescription and Over-the-Counter Drugs – A Guide for NHS and Local Authority Commissioners. London, UK: Public Health England; 2013.

3. Estimating the National and Local Prevalence of Problem Drug Use in Scotland 2012/13. Information Statistics Division. Edinburgh, UK: Scottish Government; 2014.

4. National Pharmaceutical Forum & Scottish Medical and Scientific Advisory Committee. *Prevention and Treatment of Substance Misuse. Delivering the Right Medicine: A strategy for Pharmaceutical Care in Scotland.* Edinburgh, UK: Scottish Executive; 2005.

5. Hill D, Conroy S, Afzal A, Lang D, Steele S, Campbell D. A comparison of methadone and buprenorphine-naloxone as opioid substitution therapy: the patient perspective in NHS Lanarkshire. *J Substance Use*. 2014;20(3):168-177.

6. James L, Clark D. *Methadone versus Subutex: Recovering Heroin Users' Views on Substitute Prescribing.* Swansea, UK: Swansea University; 2011.

7. Matheson C, Bond CM, Mollison J. Attitudinal factors associated with community pharmacists' involvement in services for drug misusers. *Addiction*. 1999;94(9):1349-1359.

8. Jones L, Edge J, Love AC. The effect of educational intervention on pharmacists' attitudes to substance users. *J Substance Use*. 2005;10(5):285-292.

9. NHS Education for Scotland. *Pharmaceutical Care in Substance Misuse*. Glasgow: NHS Education for Scotland; 2007.

10. McKimm J, Jollie C, Cantillon P. ABC of learning and teaching: Web based learning. *BMJ*. 2003;326(7394):870-873.

11. Childs S, Blenkinsopp E, Hall A, Walton G. Effective e-learning for health professionals and students – barriers and their solutions. A systematic review of the literature – findings from the HeXL project. *Health Info Libr J.* 2005;22(S2):20-32.

12. Cook DA. Where are we with Web-based learning in medical education? *Med Teach*. 2006;28(7):594-598.

13. Masters K, Ellaway R. e-Learning in medical education Guide 32 Part 2: technology, management and design. *Med Teach*. 2008;30(5):474-489.

14. Maxwell S, Mucklow J. E-Learning initiatives to support prescribing. *Br J Clin Pharmacol*. 2012;74(4):621-631.

15. Cook DA, Levinson AJ, Garside S, Dupras DM, Erwin PJ, Montori VM. Internet-based learning in health professionals – a meta-analysis. *JAMA*. 2008;300(10):1181-1196.

16. Chumley-Jones HS, Dobbie A, Alford CL. Web-based learning: sound educational method or hype? A review of evaluation literature. *Acad Med.* 2002;77(S10):s86-s93.

17. Bernard RM, Abrami PC, Lou Y, et al. How does distance education compare with classroom instruction? A meta-analysis of the empirical literature. *Rev Educ Res.* 2004;74(3):379-439.

18. Tallent-Runnels MK, Thomas JA, Lan WY, et al. Teaching courses online: a review of the research. *Rev Educ Res.* 2006;76(1): 93-135.

19. Salter SM, Karia A, Sanfilippo FM, Clifford RM. Effectiveness of e-learning in pharmacy education. *Am J Pharm Educ*. 2014;78(4): Article 83.

20. Walters C, Raymont A, Galea S, Wheeler A. Evaluation of on line training for the provision of opioid substitution treatment by community pharmacists in New Zealand. *Drug Alcohol Rev.* 2012;31(7):903-910.

American Journal of Pharmaceutical Education 2016; 80 (3) Article 48.

21. Cook DA, Triola MM. Virtual patients: a critical literature review and proposed next steps. *Med Educ*. 2009;43(4):303-311.

22. Cook DA, Erwin PJ, Triola MM. Computerized virtual patients in health professions education: a systematic review and metaanalysis. *Acad Med*. 2010;85(10):1589-1602.

23. Villaume WA, Berger BA, Barker BN. Learning motivational interviewing: scripting a virtual patient. *Am J Pharm Educ*. 2006;70(2):Article 33.

24. Orr KK. Integrating virtual patients into a self-care course. *Am J Pharm Educ*. 2007;71(2):Article 30.

25. Benedict N. Virtual patients and problem-based learning in advanced therapeutics. *Am J Pharm Educ*. 2010;74(8):Article 143.
26. Benedict N, Schonder K. Patient simulation software to augment an advanced pharmaceutics course. *Am J Phar Educ*. 2011;75(2): Article 21.

27. Cavaco AM, Madeira F. European pharmacy students' experience with virtual patient technology. *Am J Phar Educ*. 2012;76(6):Article 106.

28. Benedict N, Schonder K, McGee J. Promotion of self-directed learning using virtual patient cases. *Am J Pharm Educ.* 2013;77(7): Article 151.

29. Douglass MA, Casale JP, Skirvin A, DiVall MV. A virtual patient software program to improve pharmacy student learning in a comprehensive disease management course. *Am J Pharm Educ.* 2013;77(8):Article 172.

30. Smith MA, Mohammad RA, Benedict N. Use of virtual patients in an advance therapeutics pharmacy course to promote active,

patient centred learning. *Am J Pharm Educ*. 2014;78(6):Article 125. 31. Al-Dahir S, Bryant K, Kennedy KB, Robinson DS. Online virtual patient cases versus traditional problem-based learning in advanced pharmacy practice experiences. *Am J Pharm Educ*. 2014;78(4): Article 76.

 Kolb DA. Experiential Learning: Experience as a Source of Learning and Development. New Jersey: Prentice-Hall; 1984.
 Colvin-Clark R. Scenario-Based e-Learning: Evidence-Based Guidelines on Online Workforce Learning. San Francisco, CA: Pfeiffer; 2012.

34. Cunningham DE, Zlotos L, Power A. Scottish pharmacists' perceptions and experiences of a practice-based small group learning pilot: a qualitative study. *Educ Prim Care*. 2014;25(30):155-162.

35. Department of Health. *Drug Misuse and Dependence – Guidelines on Clinical Management*. Department of Health (England), The Scottish Office Department of Health, Welsh Office and Department of Health and Social Services, Northern Ireland: 1999.

36. Department of Health. *Drug Misuse and Dependence – Guidelines on Clinical Management*. Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Irish Executive: 2007.

37. Jabbur-Lopes MO, Mesquita AR, Silva LMA, Neto ADA, Lyra Jr DP. Virtual patients in pharmacy education. *Am J Pharm Educ*. 2012;76(5):Article 92.

38. Zary N, Johnson G, Boberg J, Fors UGH. Development, implementation and pilot evaluation of a Web-based virtual patient case simulation environment – Web-SB. *BMC Med Educ*. 2006;6:1-10.

39. Loke SK, Tordoff J, Winikoff M, McDonald J, Vlugter P, Duffull SB. SimPharm: how pharmacy students made meaning of a clinical case differently in paper and simulation-based workshops. *Br J Educ Tech*. 2010; 42(5):865-874.

40. Hayton WL, Collins PL. STELLA: simulation software for pharmacokinetic software. *Am J Pharm Educ.* 1991;55:131-134.
41. Ramanathan M, Chau RI, Straubinger RM. Integration of Internet-based technologies as a learning tool in a pharmaceutical calculations course. *Am J Pharm Educ.* 1997;61(2):141-148.
42. Thompson JE. Development and use of an interactive database management system for simulated patient care experiences for pharmacy students. *Am J Pharm Educ.* 1994;58(3):324-332.
43. Chisholm MA, Dehoney J, Poirier S. Development and evaluation of a computer assisted instructional program in an advanced pharmacotherapeutics course. *Am J Pharm Educ.* 1996; 60(4):365-369.

44. Hussein G, Kawahara N. Adaptive and longitudinal pharmaceutical care instruction using an interactive voice response/ text-to-speech system. *Am J Pharm Educ*. 2006;70(2):Article 37.
45. Bindoff I, Ling T, Bereznicki L, et al. A computer simulation of community pharmacy practice for educational use. *Am J Pharm Educ*. 2014;78(9):Article 168.

46. Marriot JL. Use and evaluation of 'virtual' patients for assessment of clinical pharmacy undergraduates. *Pharm Educ*. 2006;7(4):341-349.